ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 255,82
0,93%
DAX
17 896,50
-0,14%
Brent Oil
83,755
0,26%
Bitcoin
59 287,99
1,80%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) Actualités

LXRX

Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LXRX
DateHeureSourceTitreSymboleSociété
29/04/202415h00GlobeNewswire Inc.Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/04/202413h00GlobeNewswire Inc.Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
18/04/202414h00GlobeNewswire Inc.Lexicon Pharmaceuticals to Host 2024 Investor DayNASDAQ:LXRXLexicon Pharmaceuticals Inc
03/04/202414h00GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
25/03/202414h20GlobeNewswire Inc.Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & ExpoNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/03/202413h00GlobeNewswire Inc.New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney DiseaseNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202421h25Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202412h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202412h15GlobeNewswire Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202412h05GlobeNewswire Inc.Lexicon Announces Oversubscribed $250 Million Private Placement of Equity SecuritiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202412h00GlobeNewswire Inc.Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDANASDAQ:LXRXLexicon Pharmaceuticals Inc
29/02/202422h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/01/202413h00GlobeNewswire Inc.Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/12/202323h27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LXRXLexicon Pharmaceuticals Inc
21/12/202322h15GlobeNewswire Inc.Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
30/11/202313h30GlobeNewswire Inc.Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)NASDAQ:LXRXLexicon Pharmaceuticals Inc
22/11/202313h30GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/11/202320h10GlobeNewswire Inc.INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical DataNASDAQ:LXRXLexicon Pharmaceuticals Inc
10/11/202322h01GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/11/202322h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LXRXLexicon Pharmaceuticals Inc
08/11/202313h00GlobeNewswire Inc.Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
03/11/202314h00GlobeNewswire Inc.Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023NASDAQ:LXRXLexicon Pharmaceuticals Inc
02/11/202314h00GlobeNewswire Inc.Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023NASDAQ:LXRXLexicon Pharmaceuticals Inc
01/11/202314h00GlobeNewswire Inc.INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured PatientsNASDAQ:LXRXLexicon Pharmaceuticals Inc
31/10/202321h01GlobeNewswire Inc.Lexicon Strengthens Management Team With Two New ExecutivesNASDAQ:LXRXLexicon Pharmaceuticals Inc
30/10/202321h01GlobeNewswire Inc.New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual MeetingNASDAQ:LXRXLexicon Pharmaceuticals Inc
17/10/202322h01GlobeNewswire Inc.Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National MeetingNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/10/202322h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/10/202315h00GlobeNewswire Inc.Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National MeetingNASDAQ:LXRXLexicon Pharmaceuticals Inc
09/10/202322h01GlobeNewswire Inc.INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare PatientsNASDAQ:LXRXLexicon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:LXRX

Dernières Valeurs Consultées

EU
AF
Air FranceKLM
EU
LR
Legrand
NYSE
MCD
McDonalds
EU
SGO
Cie de SaintGobain
EU
MC
Lvmh Moet Hennessy Louis...
NASDAQ
MSFT
Microsoft
NASDAQ
NVDA
NVIDIA
EU
HO
Thales
COIN
BTCUSD
Bitcoin
EU
VK
Vallourec
EU
VIV
Vivendi
EU
RNO
Renault
EU
DG
Vinci
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés